ADDITIONAL INFORMATION CONTINUED AUDITORS Grant Thornton New Zealand Audit Limited (‘Grant Thornton’) is the independent auditor of the Company. Audit fees in relation to the annual and interim financial statements were $140,850 (2024: $115,358). Grant Thornton did not receive any other fees in relation to other financial advice and services. No amounts were payable to an auditor by subsidiary companies in 2025 or 2024. EQUITY SECURITIES HELD BY DIRECTORS AS AT 16 MARCH 2026 Interests in Ordinary Shares Director Direct Indirect Dianne Angus 30,000 – Patrick Davies – 264,634 Jenny Harry – 29,663 Jonathan Pilcher 1,500,000 – Joe Basile 36,800 11,406 DIRECTORS OF SUBSIDIARY COMPANIES AT 31 DECEMBER 2025 Jon Pilcher Larry Glass Patrick Davies Neuren Pharmaceuticals Inc. √ √ Neuren Pharmaceuticals (Australia) Pty Ltd √ √ Neuren Trustee Limited √ AUSTRALIAN STOCK EXCHANGE DISCLOSURES Neuren Pharmaceuticals Limited is incorporated in New Zealand under the Companies Act 1993. The Company is not subject to Chapter 6, 6A, 6B and 6C of the Corporations Act, Australia, dealing with the acquisition of shares (such as substantial holdings and takeovers). Limitations on the acquisition of shares imposed under New Zealand law are as follows: (a) In general, securities in the Company are freely transferable and the only significant restrictions or limitations in relation to the acquisition of securities are those imposed by New Zealand laws relating to takeovers and overseas investment. (b) The New Zealand Takeovers Code creates a general rule under which the acquisition of 20% or more of the voting rights in the Company or the increase of an existing holding of 20% or more of the voting rights of the Company can only occur in certain permitted ways. These include a full takeover offer in accordance with the Takeovers Code, a partial takeover in accordance with the Takeovers Code, an acquisition approved by an ordinary resolution, an allotment approved by an ordinary resolution, a creeping acquisition (in certain circumstances), or compulsory acquisition of a shareholder holding 90% or more of the shares. (c) The New Zealand Overseas Investment Act 2005 and Overseas Investment Regulations 2005 (New Zealand) regulate certain investments in New Zealand by overseas interest. In general terms, the consent of the New Zealand Overseas Investment Office may be required where an ‘overseas person’ acquires shares in the Company that amount to 25 % or more of the shares issued by the Company, or if the overseas person already holds 25% or more, the acquisition increases that holding. Neuren Pharmaceuticals Limited Annual Report 2025 62
RkJQdWJsaXNoZXIy MjE2NDg3